Adenosine deaminase |
Catalog No.GC35250 |
La adenosina desaminasa es una enzima que cataliza la desaminaciÓn irreversible de adenosina y 2'-desoxiadenosina a inosina y 2'-desoxiinosina, respectivamente.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 9026-93-1
Sample solution is provided at 25 µL, 10mM.
Adenosine deaminase (ADA) is a key enzyme involved in the purine metabolic pathway. It has an irreversible deamination effect on adenosine and deoxyadenosine, converting them into inosine and deoxyinosine, respectively [1]. Adenosine deaminase has been found in bacteria, plants, invertebrates, vertebrates and mammals, and its amino acid sequence is highly conserved [2]. Adenosine deaminase is a signaling molecule associated with T lymphocyte activation, making it a useful marker of inflammation, especially meningitis and pleurisy [3]. The main function of adenosine deaminase in the human body is the development and maintenance of the immune system. Hereditary adenosine deaminase deficiency reduces the differentiation and maturation of lymphoid cells, leading to lymphocytopenia and severe combined immunodeficiency disease (SCID) [4]. This product is provided in powder form and is reconstituted with 20% glycerol in water. It has an activity of 150 units/mg, is stable at pH 7.0-9.0, and has a molecular weight of 33kDa (SDS-PAGE).
In vitro, adenosine deaminase (3 units/ml) can be added to cell culture media to remove exogenous adenosine for cyclic adenosine monophosphate (cAMP) measurement [5]. In vivo, pegylated adenosine deaminase (5 U/kg) treatment of streptozotocin (STZ)-induced diabetic rats for 4 weeks significantly reduced the amounts of inflammatory cytokines IL-1β, IL-6, and IL-18, alleviated proteinuria, and reduced the levels of the profibrotic marker α-SMA in renal tissue [6].
References:
[1] Sauer A V, Brigida I, Carriglio N, et al. Autoimmune dysregulation and purine metabolism in adenosine deaminase deficiency[J]. Frontiers in immunology, 2012, 3: 265.
[2] Cristalli G, Costanzi S, Lambertucci C, et al. Adenosine deaminase: functional implications and different classes of inhibitors[J]. Medicinal research reviews, 2001, 21(2): 105-128.
[3] Silva Dalsasso Joaquim L, Granzotto N, Dos Santos L F, et al. Analytical validation of an in‐house method for adenosine deaminase determination[J]. Journal of Clinical Laboratory Analysis, 2019, 33(3): e22823.
[4] Bradford K L, Moretti F A, Carbonaro-Sarracino D A, et al. Adenosine deaminase (ADA)-deficient severe combined immune deficiency (SCID): molecular pathogenesis and clinical manifestations[J]. Journal of clinical immunology, 2017, 37: 626-637.
[5] Iyer S V, Ranjan A, Elias H K, et al. Genome-wide RNAi screening identifies TMIGD3 isoform1 as a suppressor of NF-κB and osteosarcoma progression[J]. Nature Communications, 2016, 7(1): 13561.
[6] Garrido W, Jara C, Torres A, et al. Blockade of the adenosine A3 receptor attenuates caspase 1 activation in renal tubule epithelial cells and decreases interleukins IL-1β and IL-18 in diabetic rats[J]. International Journal of Molecular Sciences, 2019, 20(18): 4531.
Animal experiment [1]: | |
Animal models | SD rat |
Preparation method | Adenosine deaminase was PEGylated. Following one month from diabetes induction in rats, adenosine deaminase (5 U/kg) was administered weekly by intraperitoneal injection for a four-week period. |
Dosage form | 5 U/kg; i.p. |
Applications | In the urine of diabetic rats that were treated with Adenosine deaminase, a significant decrease in the amount of the inflammatory cytokines IL-1β, IL-6, and IL-18. |
References: |
Cas No. | 9026-93-1 | SDF | |
Canonical SMILES | [Adenosine deaminase] | ||
Formula | M.Wt | ~33 kDa (SDS-PAGE) | |
Solubility | Buffered aqueous glycerol solution | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5
(Based on Reviews and 14 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *